Spondyloarthritis & psoriatic arthritis
Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures
Main finding · Hip and/or spine fractureResult — go to the resultOdds ratio 0.71 95% CI 0.59–0.85Authors' conclusion
Using a large US insurance claims database, we found evidence for a protective effect of receiving TNFis on fracture risk in patients with axSpA
Study context
- Population
- Adults 18 to 65 years with axial spondyloarthritis (axSpA) (≥1 inpatient or ≥2 outpatient ICD-9/ICD-10 codes ≥7 days apart), Merative MarketScan Database, 2006 to 20211,229 cases · 12,290 controls
- Participants
- 13,519 adults
- Comparison
- Tumor necrosis factor inhibitors (TNFis), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or no medication vs nonsteroidal anti-inflammatory drugs (NSAIDs)
- Outcome
- Hip and/or spine fracture, defined by ICD-9 or ICD-10 diagnosis or procedure codes
Methodological detailsup to 10 controls per case, unconditional logistic regression with confounder adjustment, hierarchical medication exposure
- Up to 10 controls per case
- Unconditional logistic regression with confounder adjustment
- Hierarchical medication exposure
Main finding
Hip and/or spine fracture
Odds ratio
0.71
95% CI 0.59–0.85
TNFisvs NSAIDs
OR 0.71 (95% CI 0.59–0.85)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Fracture, stratified by sex (subgroup)
- Results similar when stratified by sex
Original publication
Association of Therapies for Axial Spondyloarthritis on the Risk of Hip and Spine Fractures. Arthritis Rheumatol. Published 21 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →